Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000122575 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries.
Int J Mol Sci
June 2024
Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium.
Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; = 395) randomizing VAD induction (vincristin/adriamycin/dexamthasone)/tandem-transplantation/thalidomide-maintenance vs. PAD induction (bortezomib/adriamycin/dexamethasone)/tandem transplantation/bortezomib maintenance, we discern how chromosomal aberrations determine long-term prognosis by different patterns of association with proliferation and treatment-dependent response, whether responses achieved by different regimens are equal regarding prognosis, and whether subpopulations of patients could be defined as treatable without upfront "novel agents" in cases of limited resources, e.g.
View Article and Find Full Text PDFImproved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients.
Ann Saudi Med
April 2024
From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Background: Multiple myeloma (MM) represents the second most common hematologic malignancy (15%). Induction with bortezomib, cyclophosphamide, and dexamthasone VCd (d: low dose dexamthasone) regimen is widely used due to its high effectiveness, low toxicity and good tolerability, particularly with renal impairment. Real-world data on the use of VCD in clinical practice is lacking.
View Article and Find Full Text PDF[Effect of fire needling on imiquimod induced psoriasis-like lesion and STAT3 pathway in mice].
Zhongguo Zhen Jiu
May 2022
Beijing Hospital of TCM Affiliated to Capital Medical University, Beijing Institute of TCM, Beijing Key Laboratory of Clinical Basic Research on Psoriasis, Beijing 100010.
Objective: To observe the effect of fire needling on psoriasis-like lesion and the signal transducer and activator of transcription 3 (STAT3) pathway in mice and compare the therapeutic effect between different interventions of fire needling therapy (surrounding technique of fire needling, fire needling at "Dazhui" [GV 14] and "Zusanli" [ST 36]).
Methods: Thirty male BALB/c mice were randomized into a blank group, a model group, a dexamthasone group, a surrounding technique group and an acupoint group, 6 mice in each one. Except the blank group, the mice in the rest groups were established as psoriasis-like lesion model by topical application with imiquimod cream, once daily, consecutively for 8 days.
Protopanaxadiol alleviates neuropathic pain by spinal microglial dynorphin A expression following glucocorticoid receptor activation.
Br J Pharmacol
August 2021
King's Lab, Shanghai Jiao Tong University School of Pharmacy, Shanghai, China.
Background And Purpose: New remedies are required for the treatment of neuropathic pain due to insufficient efficacy of available therapies. This study provides a novel approach to develop painkillers for chronic pain treatment.
Experimental Approach: The rat formalin pain test and spinal nerve ligation model of neuropathic pain were used to evaluate antinociception of protopanaxadiol.
[Erythrocytes - the new application in medicine].
Pol Merkur Lekarski
January 2013
Uniwersytet Medyczny w Lublinie, Katedra i Zakład Farmacji Stosowanej.
The new forms of drugs with better proprieties from traditional ones were sought for a long time. Erythrocytes applied as carriers of therapeutic substances are among promising. They are characterized by slower release of active substances, less toxicity, as well as better biocompatibility and biodegradation in the organism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!